Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra in Texas

This article was originally published in The Tan Sheet

Executive Summary

Thirty-three warning letters have been sent by Texas Department of Public Health to companies failing to comply with rule requiring ephedrine alkaloid-containing supplements bear a warning against sales to individuals under age 18 and include FDA's MedWatch number on labeling for AE reporting. Nine companies have come into compliance, approximately 10 referred to the Texas AG's office, with the rest pending, department says. Officials say they have not noticed an increase in AE reports since the rule became effective Sept. 1 (1"The Tan Sheet" Sept. 10, 2001, In Brief)...

You may also be interested in...



Ephedrine

Texas Dept. of Health's enforcement of ephedrine rule, which requires supplement labeling to carry FDA's MedWatch number and warning against sales to persons 17 or younger, commenced Sept. 1, DoH confirms Sept. 6. "Whether or not enforcement will include detaining mislabeled products will be determined on a case-by-case basis," department says. Similar provisions have been added to California bill making its way through state legislature. SB 397 cleared Senate June 7. Amendments added during Assembly Health Committee review restrict ephedrine sales to people over 18 and require MedWatch number on label. Assembly Appropriations Cmte. slated to review bill week of Sept. 10

J&J Has Big Plans For Robotic Surgery In 2020

The company’s leadership discussed its recent investments in robotic surgery technology during Johnson & Johnson’s 2019 fourth-quarter earnings call on 22 January. The company will provide more information on its robotic surgery platforms at its investors meeting in May in New York.

Study Links Paclitaxel To Lower-Leg Amputations

New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.

Topics

UsernamePublicRestriction

Register

PS093516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel